Medications Development for Stimulant Dependence

Researchers: Malcolm S. Reid, PhD, Paul Casadonte, MD, John Rotrosen, MD and others

Cocaine and amphetamine dependence are significant public health problems. No pharmacological agent is currently approved for treatment of cocaine and amphetamine dependence and treatment for addiction to stimulants is primarily psychosocial and behavioral. In collaboration with the National Institute on Drug Abuse (NIDA), the New York University School of Medicine, Medications Development for Stimulant Dependence (MDS) Clinical Trials Site runs studies to identify and develop pharmacological agents to treat stimulant dependence. These studies are run on a contract basis with the sponsor, NIDA. The primary objective of this research collaboration is to conduct Phase I safety and Phase II efficacy clinical trials with established and investigational medications.

Current Clinical Studies